By Kamal Choudhury and Christy Santhosh
(Reuters) -The U.S. Food and Drug Administration on Thursday approved Kura Oncology and Japanese partner Kyowa Kirin's once-daily pill, Komzifti, to treat a rare form of blood cancer that has returned or stopped responding to treatment.
The drug is approved for acute myeloid leukemia patients with an NPM1 mutation, a genetic change found in about 30% of cases.
Acute myeloid leukemia is an aggressive cancer of the blood and bone marrow.
Kura said the drug will be available within the next few business days at a price of $48,500 for a one-month supply.
With the approval, Kura's drug now competes with Syndax Pharmaceuticals' Revuforj, which was approved for the same indication by the FDA last month.
Komzifti’s approval comes with a boxed warning for differentiation syndrome and an additional warning for QTc interval prolongation, a delay in the heart’s electrical recovery after a beat, and potential harm to unborn babies.
A boxed warning is the U.S. Food and Drug Administration’s strongest alert for serious or life-threatening risks and appears prominently on a drug’s label to warn doctors and patients.
Revuforj carries a boxed warning for QTc interval prolongation, giving Kura “a significant competitive advantage,” according to Wedbush analysts.
Kura's Chief Medical Officer Mollie Leoni said the risk of QTc prolongation with Komzifti is low, adding it is “extraordinarily unlikely” to lead to a boxed warning.
The company said it is in dialogue with the FDA about potential steps post-approval that could help refine the labeling.
Under the terms of its collaboration with Kyowa, Kura is responsible for manufacturing Komzifti and will lead commercialization in the United States, while Kyowa handles commercial strategy and development outside the U.S.
Analysts, on average, expect Komzifti to have annual sales of $1.32 billion by 2031, according to LSEG data.
(Reporting by Kamal Choudhury and Christy Santhosh in Bengaluru; Editing by Shailesh Kuber and Tasim Zahid)
LATEST POSTS
- 1
Israel has clear objectives south of Litani River, but will face difficult choices further north - 2Pick Your Favored pizza beating
- 3The next frontier in space is closer than you think – welcome to the world of very low Earth orbit satellites
- 4Why this Iranian island looks like Mars after it rains
- 5Hostages as leverage: Iran's secret demand aimed at crippling Israel's agriculture
- Addressing sleep apnea early might decrease chances of developing Parkinson's disease
- Whale stranded off Germany for days found stuck again
- A rare whale is having an encouraging season for births. Scientists warn it might still go extinct
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- Share your pick for the miniature headphones that you generally suggest!
- Highlight Correlation of Microsoft Surface Book and Surface Genius Workstations for Determination
- Kidneys from Black donors are more likely to be thrown away − a bioethicist explains why
- Kids who get 2-month vaccines on time 7 times more likely to receive MMR shot: Study
- International issues on the agenda as Frances's Macron visits China
